Providence cancer researchers make national headlines
Eric Tran, Ph.D.
Rom Leidner, M.D.
Providence Cancer Institute is among a handful of centers in the world capable of developing a type of cancer immunotherapy called adoptive cell therapy.
Under the leadership of Eric Tran, Ph.D., and Rom Leidner, M.D., our team has pioneered a second-generation adoptive cell therapy using genetically engineered T cells, a type of immune cell capable of destroying cancer cells.
Their innovative work is published in the New England Journal of Medicine article Neoantigen T-Cell Receptor-Gene Therapy in Pancreatic Cancer available in the June
2, 2022, issue.
- New England Journal of Medicine article
- Providence blog post
- NY Times
- Associated Press
- NBC News (web story)
- Portland Business Journal
Philanthropy funds more than 70% of our cancer research. This work would not be possible without the generous support of donors and the participation of patients whom we are privileged to serve. Thank you.